Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVX7 in advanced cervical cancer
NCT06315257Phase 1Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2025
- Primary completion
- Jun 2029
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pBI-11 in Cervical Cancer (CC) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Safety of PVX7 as assessed by adverse events at 12 months and Feasibility of PVX7 at 12 months. Started Jul 2025; status: recruiting.
02
Drugs
pBI-11
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06315257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06315257.